EcoDrugPlus

Cytochrome P450 3a30

Ensembl ID : ENSIPUG00000012596
Gene Symbol: LOC108258760
3 Cross references
572 Possible Orthologues:

Cytochrome P450 3a40

Ensembl ID : ENSIPUG00000017942
Gene Symbol: LOC108257387
3 Cross references
536 Possible Orthologues:

Cytochrome P450 Family 19 Subfamily A Member 1

Ensembl ID : ENSIPUG00000009269
Gene Symbol: CYP19A1
4 Cross references
244 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1a

Ensembl ID : ENSIPUG00000004605
Gene Symbol: DGAT1A
3 Cross references
191 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1b

Ensembl ID : ENSIPUG00000005568
Gene Symbol: DGAT1B
4 Cross references
190 Possible Orthologues:

Dihydroorotate Dehydrogenase

Ensembl ID : ENSIPUG00000011595
Gene Symbol: DHODH
3 Cross references
172 Possible Orthologues:

Dihydropyrimidine Dehydrogenase A, Tandem Duplicate 1

Ensembl ID : ENSIPUG00000009281
Gene Symbol: DPYDA.1
3 Cross references
211 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSIPUG00000008852
Gene Symbol: DDR2
3 Cross references
192 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2a

Ensembl ID : ENSIPUG00000005192
Gene Symbol: DDR2A
3 Cross references
204 Possible Orthologues:

Dopamine Receptor D1

Ensembl ID : ENSIPUG00000010246
Gene Symbol: DRD1
4 Cross references
188 Possible Orthologues:

Dopamine Receptor D1b

Ensembl ID : ENSIPUG00000012849
Gene Symbol: DRD1B
1 Cross references
198 Possible Orthologues:

Dopamine Receptor D2a

Ensembl ID : ENSIPUG00000011931
Gene Symbol: DRD2A
3 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).